Shinichi Makita

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 20

Top Topics

Peritoneal Dialysis

Hodgkin Lymphoma

Top Venues

Cancer medicine

Pathology international

Expert opinion on biological therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano-Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer medicine (2022)
Ulrich Jäger, Constantine S Tam, Peter Borchmann, Joseph P McGuirk, Marianne Johansen, Edmund K Waller, Samantha M Jaglowski, Charalambos Andreadis, Stephen R Foley, Jason R Westin, Isabelle Fleury, P Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Andre Salles, Stephen J Schuster, Fiona He, Richard T Maziarz, Sebastian Mayer, Shinichi Makita, Marie J Kersten, Monalisa Ghosh, Nina D Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R Bishop
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood advances 6 (16) (2022)
Koji Izutsu, Shinichi Makita, Kisato Nosaka, Makoto Yoshimitsu, Atae Utsunomiya, Shigeru Kusumoto, Satoko Morishima, Kunihiro Tsukasaki, Toyotaka Kawamata, Takaaki Ono, Shinya Rai, Hiroo Katsuya, Jun Ishikawa, Hironori Yamada, Kazunobu Kato, Masaya Tachibana, Yasuyuki Kakurai, Nobuaki Adachi, Kensei Tobinai, Kentaro Yonekura, Kenji Ishitsuka
An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood (2022)
Takahiro Fujino, Dai Maruyama, Akiko-Miyagi Maeshima, Yo Saito, Hanae Ida, Rika Hosoba, Sayako Yuda, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Junya Kuroda, Koji Izutsu
The outcome of watchful waiting in patients with previously treated follicular lymphoma. Cancer medicine 11 (10) (2022)
Atae Utsunomiya, Koji Izutsu, Tatsuro Jo, Shinichiro Yoshida, Kunihiro Tsukasaki, Kiyoshi Ando, Ilseung Choi, Yoshitaka Imaizumi, Koji Kato, Mitsutoshi Kurosawa, Shigeru Kusumoto, Takashi Miyagi, Eiichi Ohtsuka, Osamu Sasaki, Hirohiko Shibayama, Kazuya Shimoda, Yasushi Takamatsu, Kuniko Takano, Kentaro Yonekura, Shinichi Makita, Jun Taguchi, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results. Cancer science 113 (8) (2022)
Saaya Tsutsué, Shinichi Makita, Jingbo Yi, Bruce Crawford
Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis. PloS one 17 (5) (2022)
Tomotaka Suzuki, Dai Maruyama, Akiko Miyagi-Maeshima, Junko Nomoto, Kinuko Tajima, Yuta Ito, Shunsuke Hatta, Sayako Yuda, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Hirokazu Taniguchi, Koji Izutsu, Yukio Kobayashi, Kensei Tobinai
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer medicine 10 (15) (2021)
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Yoshikazu Hori, Hanae Ida, Rika Hosoba, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma: a study of 76 patients. Pathology international 71 (10) (2021)
Wataru Munakata, Yukari Shirasugi, Kensei Tobinai, Makoto Onizuka, Shinichi Makita, Rikio Suzuki, Dai Maruyama, Hidetsugu Kawai, Koji Izutsu, Tadashi Nakanishi, Sari Shiba, Seichiro Hojo, Kiyoshi Ando
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer science 112 (3) (2021)
Shinichi Makita, Dai Maruyama, Kensei Tobinai
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. OncoTargets and therapy 13 (2020)
Yo Saito, Shinichi Makita, Shotaro Chinen, Momoko Kito, Takahiro Fujino, Hanae Ida, Rika Hosoba, Takashi Tanaka, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Akiko Miyagi Maeshima, Hiromichi Matsushita, Koji Izutsu
Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour. British journal of haematology 190 (6) (2020)
Shinichi Makita, Rika Hosoba, Kensei Tobinai
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert opinion on drug safety 19 (9) (2020)
Takafumi Shichijo, Dai Maruyama, Nobuhiko Yamauchi, Akiko Miyagi Maeshima, Masato Sugano, Sayako Yuda, Kinuko Tajima, Hiroaki Kurihara, Kaoru Shimada, Tomotaka Suzuki, Kosuke Toyoda, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Yukio Kobayashi, Hirokazu Taniguchi, Yosuke Minami, Koji Izutsu, Kensei Tobinai
Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma. Cancer medicine 9 (23) (2020)
Shinichi Makita, Dai Maruyama, Akiko Miyagi Maeshima, Hirokazu Taniguchi, Sayako Yuda, Kosuke Toyoda, Nobuhiko Yamauchi, Suguru Fukuhara, Wataru Munakata, Yukio Kobayashi, Hiroaki Kurihara, Koji Izutsu, Kensei Tobinai
A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma. Asia-Pacific journal of clinical oncology 16 (3) (2019)
Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, Sung-Won Kim, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Shinichi Makita, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin. Clinical case reports 7 (12) (2019)
Yuta Ito, Shinichi Makita, Kensei Tobinai
Development of new agents for peripheral T-cell lymphoma. Expert opinion on biological therapy 19 (3) (2019)
Yuta Ito, Shinichi Makita, Akiko Miyagi Maeshima, Shunsuke Hatta, Sayako Yuda, Tomotaka Suzuki, Suguru Fukuhara, Wataru Munakata, Hirokazu Taniguchi, Tatsuya Suzuki, Dai Maruyama, Koji Izutsu
EBV-encoded RNA1-positive cells in the bone marrow specimens of patients with EBV-negative lymphomas and sarcomas. Pathology international 69 (7) (2019)
Junko Watanabe, Shinichi Makita, Yuta Ito, Shunsuke Hatta, Tomotaka Suzuki, Sayako Yuda, Akiko Miyagi Maeshima, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Dai Maruyama, Sung-Won Kim, Koji Izutsu
Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase. Annals of hematology 97 (9) (2018)
Shinichi Makita, Kiyoshi Yoshimura, Kensei Tobinai
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer science 108 (6) (2017)
Shinichi Makita, Kensei Tobinai
Mogamulizumab for the treatment of T-cell lymphoma. Expert opinion on biological therapy 17 (9) (2017)